A petition urges the FDA to allow certain radiology AI software updates via postmarket study requirements instead of new 510(k) applications.
Key Details
- 1Petition submitted to the FDA seeks a streamlined pathway for radiology AI software with prior 510(k) clearance.
- 2Proposal targets CADx, CADe/x, CADt, and medical image analyzer software types under specified FDA regulations.
- 3Vendors with cleared devices could forgo new 510(k) submissions for new features, provided robust postmarket measures are in place.
- 4Existing 510(k) pathway would remain as an option; the new pathway would be partially exempt under defined conditions.
- 5FDA is accepting comments on the proposal until February 27, 2026.
- 6The proposal aims to close the 'innovation gap' between the U.S. and other regions, citing more limited AI diagnostic offerings in the U.S.
Why It Matters
If adopted, this pathway could accelerate the deployment of AI innovations in U.S. radiology by reducing regulatory redundancy, addressing concerns about lagging AI adoption compared to Europe. It signals ongoing regulatory evolution in medical imaging AI oversight.
Source
AuntMinnie
Related News
•AuntMinnie
Vast Majority of FDA-Cleared Radiology AI Devices Lack Outcome Trials
Only 0.3% of FDA-cleared radiology AI devices have registered trials on patient outcomes, raising concerns about evidence standards.
•Radiology Business
Radiology Partners Urges FDA for Clarity on Imaging AI Regulations
Radiology Partners and Mosaic Clinical Technologies petition the FDA for clearer regulatory guidelines on imaging AI vision-language models.
•Radiology Business
FDA Solicits Public Input on Regulating Generative AI in Medical Devices
The FDA is seeking public feedback on how to regulate generative AI in medical devices, recognizing both its promise and risks.